Advertisement

Nutraceuticals in Cardiovascular Diseases

  • Csaba K. Zoltani
Chapter

Abstract

Cardiac dysfunction in animals, under certain conditions, can be alleviated or prevented by the consumption of nutraceuticals. Nutraceuticals, which are naturally occurring non-drug plant components, are able to affect the genetic system and physiological systems of animals following their absorption. This chapter addresses the mode of action of specific phytotherapeutic components in common cardiac diseases of animals.

Keywords

Animal cardiac dysfunction Cardiac diseases Nutraceuticals Mode of action of nutraceuticals 

References

  1. Aggarwal BB, Harikumar KB (2009) Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol 41(1):40–59PubMedGoogle Scholar
  2. Ahmad A, Li Y, Bao B et al (2014) Epigenetic regulation of miRNA-cancer stem cell nexus by nutraceuticals. Mol Nutr Food Res 58(1):79–86PubMedGoogle Scholar
  3. Alwi I, Santoso T, Suyomo S et al (2008) The effect of curcumin on lipid level in patients with acute coronary syndrome. Acta Med Indones 40(4):201–210PubMedGoogle Scholar
  4. Araim O, Ballantyne J, Waterhouse AL et al (2002) Inhibition of vascular smooth muscle cell proliferation with red wine and red wine polyphenols. J Vasc Surg 35(6):1226–1231PubMedGoogle Scholar
  5. Aronson JK (2017) Defining ‘nutraceuticals’: neither nutritious nor pharmaceutical. Br J Clin Pharmacol 83:8–19PubMedGoogle Scholar
  6. Atkins C, Bonagura J, Ettinger P et al (2009) Guidelines for the diagnosis and treatment of canine chronic valvular heart disease. J Vet Intern Med 23:1142–1150PubMedGoogle Scholar
  7. Babbar N, Oberoi HS, Sandhu SK (2015) Therapeutic and nutraceutic potential of bioactive compounds extracted from fruit residues. Crit Rev Food Sci Nutr 55:319–337PubMedGoogle Scholar
  8. Berman AY, Motechin RA, Wiesenfeld MY et al (2017) The therapeutic potential of resveratrol: a review of clinical trials. NPJ Precis Oncol 1(1):35PubMedPubMedCentralGoogle Scholar
  9. Bhattacharyya A, Roy D (2015) Nutraceuticals in livestock and poultry. New India Publishing Agency, New DelhiGoogle Scholar
  10. Brasier AR (2006) The NF-kappaB regulatory network. Cardiovasc Toxicol 6(2):111–130PubMedGoogle Scholar
  11. Buczinski S, Rezakhani A, Boerboom D (2010) Heart disease in cattle: diagnosis, therapeutic approaches and prognosis. Vet J 184:258–263PubMedGoogle Scholar
  12. Calder PC (2004) n-3 fatty acids and cardiovascular disease: evidence explained and mechanisms explored. Clin Sci (Lond) 107(1):1–11Google Scholar
  13. Cannavo A, Komici K, Bencivenga L et al (2018) GRK2 as a therapeutic target for heart failure. Expert Opin Ther Targets 22(1):75–83PubMedGoogle Scholar
  14. Cardoso SM, Pereira OR, Seca AML et al (2015) Seaweeds as preventive agents for cardiovascular diseases: from nutrients to functional foods. Mar Drugs 13:6838–6865PubMedPubMedCentralGoogle Scholar
  15. Chen QM, Maltagliati AJ (2018) Nrf2 at the heart of oxidative stress and cardiac protection. Physiol Genomics 50(2):77–97PubMedGoogle Scholar
  16. Chen B, Lu Y, Chen Y et al (2015) The role of Nrf2 in oxidative stress-induced endothelial injuries. J Endocrinol 225(3):R83–R99PubMedGoogle Scholar
  17. Cheng HM, Koutsidis G, Lodge JK et al (2017) Tomato and lycopene supplementation and cardiovascular risk factors: a systematic review and meta-analysis. Atherosclerosis 257:100–108PubMedGoogle Scholar
  18. Cho HT, Salvia-Trujillo L, Kim J et al (2014) Droplet size and composition of nutraceutical nanoemulsions influences bioavailability of long chain fatty acids and Coenzyme Q10. Food Chem 156:117–122PubMedGoogle Scholar
  19. Choi EJ, Bae SM, Ahn WS (2008) Antiploriferative effects of quercetin through cell cycle arrest and apoptosis in human breast cancer MDA-MB-453 cells. Arch Pharm Res 31:1281–1285PubMedGoogle Scholar
  20. Cicero AFG, Colletti A (2018) Handbook of nutraceuticals for clinical use. Springer, ChamGoogle Scholar
  21. Dabbou S, Gasco L, Rotolo L et al (2018) Effects of dietary alfalfa flavonoids on the performance, meat quality and lipid oxidation of growing rabbits. Asian-Australas J Anim Sci 31(2):270–277PubMedGoogle Scholar
  22. Devi S, Jani RG (2009) Review on nutritional management of cardiac disorders in canines. Vet World 2(12):482–485Google Scholar
  23. Dousip A, Matanjun P, Sulaiman MR et al (2014) Effect of seaweed mixture intake on plasma lipid and antioxidant profile of hypercholeserolaemic rats. J Appl Physicol 26:999–1008Google Scholar
  24. Duthie GG, Wahle KW, James WP (1989) Oxidants, antioxidants and cardiovascular disease. Nutr Res Rev 2(1):51–62PubMedGoogle Scholar
  25. Ferguson JF, Hooman A, Gerszten RE et al (2016) Nutrigenomics, the microbiome, and gene-environment interactions: new directions in cardiovascular disease research, prevention and treatment. Circ Cardiovasc Genet 9:291–313PubMedGoogle Scholar
  26. Ferreira FS, Barretto FL, Fabres A et al (2016) Cardiac markers in five different breeds of rabbits (Oryctolagus cuniculus Linnaeus, 1758) used for cardiovascular research. Pesq Vet Bras 36(8):737–742Google Scholar
  27. Francis GS, Benedict C, Johnstone DE et al (1990) Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. Circulation 82:1724–1729PubMedGoogle Scholar
  28. Gadberry S (2012) Mineral and vitamin supplementation of beef cows in Arkansas. https://www.uaex.edu/publications/pdf/FSA-3035.pdf
  29. Galanakis C (ed) (2017) Nutraceutical and functional food components. Academic Press, New YorkGoogle Scholar
  30. Gordon JW, Shaw JA, Kirshenbaum LA (2011) Multiple facets of NF-kB in the heart: to be or not to NF-kB. Circ Res 108:1122–1132PubMedGoogle Scholar
  31. Grassi D, Desideri G, Di Giosia F et al (2013) Tea, flavonoids, and cardiovascular health: endothelial protection. Am J Clin Nutr 98(Suppl 6):1660S–1666SPubMedGoogle Scholar
  32. Greenpet (2015) Minerals for healthy animals. https://www.greenpet.com.au/minerals-for-healthy-animals/
  33. Guerrero L, Castillo J, Quinones M et al (2012) Inhibition of angiotensin-converting enzyme activity by flavonoids: structure-activity relationship studies. PLoS One 7(11):1–11Google Scholar
  34. Gupta C, Patchva S, Aggarwal BG (2013) Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J 15(1):195–218PubMedPubMedCentralGoogle Scholar
  35. Harker-Murray AK, Tajik AJ, Ishikura F et al (2000) The role of coenzyme Q10 in the pathophysiology and therapy of experimental congestive heart failure in the dog. J Card Fail 6(3):233–242PubMedGoogle Scholar
  36. Hayden MS, Ghosh S (2012) NF-κB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev 26:203–234PubMedPubMedCentralGoogle Scholar
  37. Heim KE, Tagliaferro AR, Bobilya DJ (2002) Flavonoid antioxidants: chemistry, metabolism and structure-activity relationships. J Nutr Biochem 13(10):572–584PubMedPubMedCentralGoogle Scholar
  38. Hollman PCH, Cassidy A, Comte B et al (2011) The biological relevance of direct antioxidant effects of polyphenols for cardiovascular health in humans is not established. J Nutr 141:989S–1009SPubMedGoogle Scholar
  39. Houston MC (2010) The role of cellular micronutrient analysis, nutraceuticals, vitamins, antioxidants and minerals in the prevention and treatment of hypertension and cardiovascular disease. Ther Adv Cardiovasc Dis 4(3):165–183PubMedGoogle Scholar
  40. Irino Y, Toh R, Nagao M et al (2016) 2-Aminobutyric acid modulates glutathione homeostasis in the myocardium. Sci Rep 6:36749PubMedPubMedCentralGoogle Scholar
  41. Jiang Y, Zheng W (2005) Cardiovascular toxicities upon manganese exposure. Cardiovasc Toxicol 5(4):345–354PubMedPubMedCentralGoogle Scholar
  42. Jones WE (1997) Nutraceuticals for equine practice. J Equine Vet Sci 17(11):562–572Google Scholar
  43. Khurana S, Venkataraman K, Hollingsworth A et al (2013) Polyphenols: benefits to the cardiovascular system in health and in aging. Nutrients 5:3779–3827PubMedPubMedCentralGoogle Scholar
  44. Klevay LM (2000) Cardiovascular disease from copper deficiency-a history. J Nutr 130:489S–492SPubMedGoogle Scholar
  45. Larson AJ, Symons JD, Jalili T (2012) Therapeutic potential of quercetin to decrease blood pressure: review of efficacy and mechanisms. Adv Nutr 3:39–46PubMedPubMedCentralGoogle Scholar
  46. Lee MT, Lin WC, Yu B et al (2017) Antioxidant capacity of phytochemicals and their potential effects on oxidative status in animals. Asian-Australas J Anim Sci 30:299–308PubMedGoogle Scholar
  47. Li Y, Sarkar FH (2015) Targeting epigenetically deregulated miRNA by nutraceuticals: focusing on cancer prevention and treatment. Curr Pharm Rep 1:1–10Google Scholar
  48. Li SH, Liu XX, Bai YY et al (2010) Effect of oral isoflavone supplementation on vascular endothelial function in postmenopausal women: a meta-analysis of randomized placebo-controlled trials. Am J Clin Nutr 91:480–486PubMedGoogle Scholar
  49. Lockwood B (2007) Nutraceuticals, 2nd edn. Pharmaceutical Press, LondonGoogle Scholar
  50. Loynachan A (2010) ‘Heart attacks’ and heart disease in horses. Equine Dis Q 19(4):5–6Google Scholar
  51. Luo X, Pan Z, Shan H et al (2013) MicroRNA-26 governs profibrillatory inward-rectifier potassium current changes in atrial fibrillation. J Clin Invest 123:1939–1951PubMedPubMedCentralGoogle Scholar
  52. Maegdefessel L (2014) The emerging role of microRNAs in cardiovascular disease. J Intern Med 275:633–644Google Scholar
  53. Magyar K, Halmosi R, Palfi A et al (2012) Cardioprotection by resveratrol: a human clinical trial in patients with stable coronary artery disease. Clin Hemorheol Microcirc 50(3):179–187PubMedGoogle Scholar
  54. Marr CM, Bowen M (2010) Cardiology of the horse, 2nd edn. Saunders Elsevier, PhiladelphiaGoogle Scholar
  55. Matos RS, Baroncini LAV, Precoma LB et al (2012) Resveratrol causes antiatherogenic effects in an animal model of atherosclerosis. Arq Bras Cardiol 98(2):136–142PubMedGoogle Scholar
  56. McClements DJ (2015) Nanoscale nutrient delivery systems for food applications: improving bioactive dispersibility, stability, and bioavailability. J Food Sci 80(7):1602–1611Google Scholar
  57. Mishra S, Singh RB, Dwivedi SP et al (2009) Effects of nutraceuticals on genetic expressions. Open Nutraceuticals J 2:70–80Google Scholar
  58. Mozaffarian D, Wu JHY (2011) Omega-3 fatty acids and cardiovascular disease. J Am Coll Cardiol 58(3):2047–2067PubMedGoogle Scholar
  59. Nacera H, Gregory T, Sihem B et al (2017) Green tea beverage and epigallocatecihin gallate attenuate nicotine cardiotocytotoxicity in rat. Acta Pol Pharm 74(1):277–287Google Scholar
  60. National Research Council (2007) Nutrient requirements of horses, 6th revised edn. National Academic Press, Washington, DCGoogle Scholar
  61. Neary JM, Booker CW, Wildman BK (2016) Right-sided congestive heart failure in North American feedlot cattle. J Vet Intern Med 30:326–334PubMedGoogle Scholar
  62. Nielsen J, Keasling JD (2016) Engineering cellular metabolism. Cell 164:1185–1197Google Scholar
  63. Ono K, Kuwabara Y, Han J (2011) MicroRNAs and cardiovascular diseases. FEBS J 276(10):1619–1633Google Scholar
  64. Oyama MA (2013) Using cardiac biomarkers in veterinary practice. Vet Clin North Am Small Anim Pract 43(6):1261–1272PubMedGoogle Scholar
  65. Pandey NN, Dar AA, Mondal DB et al (2011) Bovine colostrum: a veterinary nutraceutical. J Vet Med Anim Health 3(3):31–35Google Scholar
  66. Peek SF, Divers TJ (2018) Rebhun’s diseases of dairy cattle, 3rd edn. Elsevier, St LouisGoogle Scholar
  67. Phuah NH, Nagoor NH (2014) Regulation of microRNAs by natural agents: new strategies in cancer therapies. Biomed Res Int 2014:804510PubMedPubMedCentralGoogle Scholar
  68. Pomeroy LA (2011) The equine heart: beyond the x-factor. Holistic Horse. https://holistichorse.com/health-care/the-equine-heart-beyond-the-x-factor/
  69. Potenza MA, Marasciulo FL, Tarquinio M et al (2007) EGCG, a green tea polyphenol, improves endothelial function and insulin sensitivity, reduces blood pressure, and protects against myocardial I/R injury in SHR. Am J Physiol Endocrinol Metab 292:E1378–E1387PubMedGoogle Scholar
  70. Prochazkova D, Bousova L, Wilhelmmova N (2011) Antioxidant and prooxidant properties of flavonoids. Fitoterapia 82:513–523PubMedGoogle Scholar
  71. Raisbeck MF (2000) Selenosis. Vet Clin North Am Food Anim Pract 16(3):465–480PubMedGoogle Scholar
  72. Rudra PK, Nair SSD, Leitch JW et al (2001) Omega-3 polyunsaturated fatty acids and cardiac arrhythmias. In: Wildman REC (ed) Handbook of nutraceuticals and functional foods. CRC Press, Boca Raton, p 331Google Scholar
  73. Sacks FM, Lichtenstein A, Van Horn L et al (2006) Soy protein, isoflavones, and cardiovascular health: an American Heart Association science advisory for professionals from the nutrition committee. Circulation 113:1034–1044PubMedGoogle Scholar
  74. Satta S, Mahmoud AM, Wilkinson FI et al (2017) The role of Nrf2 in cardiovascular function and disease. Oxid Med Cell Long 2017:9237263Google Scholar
  75. Scalbert A, Manach C, Morand C et al (2005) Dietary polyphenols and the prevention of diseases. Crit Rev Food Sci Nutr 45(4):287–306PubMedGoogle Scholar
  76. Shankar TNB, Shantha NV, Ramesh HP (1980) Toxicity studies on tumeric (Curcuma longa): acute toxicity studies in rats, guinea pigs & monkeys. Indian J Exp Biol 18:73–75PubMedGoogle Scholar
  77. Simopoulos AP (2002) The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed Pharmacother 56(8):365–379Google Scholar
  78. Sisson DD (2004) Neuroendocrine evaluation of cardiac disease. Vet Clin North Am Small Anim Pract 34:1105–1126PubMedGoogle Scholar
  79. Small EM, Frost RJA, Olson EN (2010) MicroRNAs add a new dimension to cardiovascular disease. Circulation 121(8):1022–1032PubMedPubMedCentralGoogle Scholar
  80. Smith CE, Freeman LM, Rush JE et al (2007) Omega-3 fatty acids in boxer dogs with arrhythmogenic right ventricular cardiomyopathy. J Vet Intern Med 21:265–273PubMedGoogle Scholar
  81. Souyoul SA, Saussy KP, Lupo MP (2018) Nutraceuticals: a review. Dermatol Ther (Heidelb) 8(1):5–16Google Scholar
  82. Taillon C, Andreasen A (2000) Veterinary nutraceutical medicine. Can Vet J 41:231–234PubMedPubMedCentralGoogle Scholar
  83. Tarcin O, Yavuz DG, Ozben B et al (2009) Effect of vitamin D deficiency and replacement on endothelial function in asymptomatic subjects. J Clin Endocrinol Metab 94(10):4023–4030PubMedGoogle Scholar
  84. Tokunaga M, Takahashi T, Singh RB (2013) Nutrition and epigenetics. Med Epigenet 1:70–77Google Scholar
  85. Tousoulis D, Kampoli AM, Tentolouris C et al (2012) The role of nitric oxide on endothelial function. Curr Vasc Pharmacol 10(1):4–18PubMedGoogle Scholar
  86. Ubbink JB (2001) Coenzyme Q as a marker of oxidative stress in coronary artery disease. In: Kagan V, Quinn PJ (eds) Coenzyme Q: molecular mechanisms in health and disease (modern nutrition). CRC Press, Boca RatonGoogle Scholar
  87. Valen G, Yan Z, Hansson GK (2001) Nuclear factor kappa-B and the heart. J Am Coll Cardiol 38(2):307–314PubMedGoogle Scholar
  88. Van Der Vekens N, Decloedt A, De Clercq D et al (2012) The use of cardiac biomarkers in veterinary medicine: the equine perspective. Vlaams Diergeneeskundig Tijdschrift 2012(81):319–327Google Scholar
  89. Varzakas V, Zakynthinos G, Verpoort F (2016) Plant food residues as a source of nutraceuticals and functional foods. Foods 5:88PubMedCentralGoogle Scholar
  90. Vickers KC, Rye KA, Tabet F (2014) MicroRNA in the onset and development of cardiovascular disease. Clin Sci (Lond) 126:183–194Google Scholar
  91. Wang X, Lv H, Gu Y (2014) Protective effect of lycopene on cardiac function and myocardial fibrosis after acute myocardial infarction in rats via the modulation of p38 and MMP-9. J Mol Histol 45:113–120PubMedGoogle Scholar
  92. Wang T, Li Q, Bi K (2018) Bioactive flavonoids in medicinal plants: structure, activity and biological fate. Asian J Pharm Sci 13:12–23Google Scholar
  93. Wildman REC (ed) (2001) Handbook of nutraceuticals and functional foods. CRC Press, Boca RatonGoogle Scholar
  94. Zoltani CK (2014) Cardiovascular toxicity biomarkers. In: Gupta RC (ed) Biomarkers in toxicology. Elsevier-Academic Press, AmsterdamGoogle Scholar
  95. Zoltani CK (2016) Nutraceuticals in cardiovascular diseases. In: Gupta RC (ed) Nutraceuticals, efficacy, safety and toxicity. Elsevier-Academic Press, AmsterdamGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Csaba K. Zoltani
    • 1
  1. 1.Emeritus US Army Research LabAberdeen Proving GroundAberdeenUSA

Personalised recommendations